1. AB0500 Development of a New Methotrexate-Specific Adherence Tool for use in the Management of Patients with Rheumatoid Arthritis. (9th June 2015) Authors: Aassi, M.; Dias Barbosa, C.; Bernasconi, C.; Brethous, M.; Arnould, B.; Curtis, J.R. Journal: Annals of the rheumatic diseases Issue: Volume 74(2015)Supplement 2 Page Start: 1065 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. First‐in‐human study demonstrating the safety and clinical efficacy of novel anti‐IL‐17A monoclonal antibody CJM112 in moderate to severe plaque psoriasis. (5th January 2021) Authors: Kaul, M.; Jarvis, P.; Rozenberg, I.; Kolbinger, F.; Di Padova, F.; Calonder, C.; Espie, P.; Rondeau, J.M.; Cebe, R.; Huber, T.; Mussmann, R.; Aassi, M.; Sligh, T.S. Journal: Journal of the European Academy of Dermatology and Venereology Issue: Volume 35:Number 5(2021) Page Start: 1143 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. SAT0255 Clinical and Radiographic Outcomes at 2 Years and the Effect of TOCILIZUMAB Discontinuation following Sustained Remission in the Second and Third Year of the ACT-RAY Study. (10th June 2014) Authors: Huizinga, T.W.; Conaghan, P.G.; Martin-Mola, E.; Schett, G.; Amital, H.; Xavier, R.M.; Troum, O.; Aassi, M.; Bernasconi, C.; Dougados, M. Journal: Annals of the rheumatic diseases Issue: Volume 73:Supplement 2(2014) Page Start: 685 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Secukinumab demonstrated sustained retention, effectiveness and safety in a real‐world setting in patients with moderate‐to‐severe plaque psoriasis: long‐term results from an interim analysis of the SERENA study. (4th July 2022) Authors: Augustin, M.; Sator, P.G.; von Kiedrowski, R.; Conrad, C.; Rigopoulos, D.; Romanelli, M.; Ghislain, P.‐D.; Torres, T.; Ioannides, D.; Aassi, M.; Schulz, B.; Jagiello, P. Journal: Journal of the European Academy of Dermatology and Venereology Issue: Volume 36:Number 10(2022) Page Start: 1796 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Twelve‐week secukinumab treatment is consistently efficacious for moderate‐to‐severe psoriasis regardless of prior biologic and non‐biologic systemic treatment: Post hoc analysis of six randomised trials. (9th February 2021) Authors: Hampton, P.; Halliday, A.; Aassi, M.; Subramanian, S.; Jain, M.; Griffiths, C.E.M. Journal: Journal of the European Academy of Dermatology and Venereology Issue: Volume 35:Number 4(2021) Page Start: 928 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗